Revolution Medicines outlines $1.6B-$1.7B 2026 operating expenses as RAS(ON) inhibitor trials expand
Source: SeekingAlpha
2026-02-25 21:18:32 ET
More on Revolution Medicines
- Revolution Medicines, Inc. (RVMD) Q4 2025 Earnings Call Transcript
- Revolution Medicines, Inc. (RVMD) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
- Merck Chooses Evolution Over Revolution - At Proposed Price, I'm Not Surprised
- Revolution Medicines reports Q4 results
- Revolution Medicines Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Revolution Medicines outlines $1.6B–$1.7B 2026 operating expenses as RAS(ON) inhibitor trials expand
Revolution Medicines Inc.
NASDAQ: RVMD
RVMD Trading
-0.85% G/L:
$97.96 Last:
132,064 Volume:
$98.93 Open:
RVMD Latest News
February 25, 2026 04:02:00 pm
Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
February 24, 2026 04:05:00 pm
Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
RVMD Stock Data
$18,541,302,498
177,467,581
0.42%
132
N/A
Biotechnology & Life Sciences
Healthcare
US
Redwood City
